# Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients

> **NCT02739100** · PHASE1 · COMPLETED · sponsor: **Rockwell Medical Technologies, Inc.** · enrollment: 13 (actual)

## Conditions studied

- End Stage Renal Disease

## Interventions

- **DRUG:** Triferic

## Key facts

- **NCT ID:** NCT02739100
- **Lead sponsor:** Rockwell Medical Technologies, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2016-07
- **Final completion:** 2016-07
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2019-02-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02739100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02739100, "Pharmacokinetics and Preliminary Bioequivalence of Triferic (Ferric Pyrophosphate Citrate) Administered Via Hemodialysate and Intravenously to Adult CKD-5HD Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02739100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*